NanoViricides restarting ebola treatment development program

Antiviral therapy company NanoViricides, Inc., announced on Monday that it is restarting its drug development program to combat ebola.

The NanoViricides ebola treatment uses an "intelligent nanomachines" approach that the company believes is superior to other therapeutics.

"We are happy to restart the ebola program, considering the public health impact of the ebola virus infection," Eugene Seymour, the CEO of NanoViricides, said. "We are in a strong financial position now, enabling us to work on this project while we continue to advance our FluCide and DengueCide therapies further towards clinical trials. We hope to create highly effective drugs against Ebola, similar to what we have achieved with our FluCide influenza drug candidate."

NanoViricides now has its own drug manufacturing facility that could produce sufficient quantities of an anti-ebola treatment after it is developed. The company currently has approximately $41 million that could be used to take at least one, and possibly another, drug candidate into human clinical trials.

The current outbreak of ebola in West Africa has killed more than 850 people. Two American healthcare workers who contracted the disease are currently being treated with an experimental therapy at Emory University in Atlanta, Ga.

There are currently no licensed drugs or vaccines for ebola.